AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32314543 — intervention group
Group type: COMPARATOR
Intervention: Manual analysis
Number of subjects: 5988
Study 32314543 — intervention group
Group type: EXPERIMENTAL
Intervention: ABACS
Number of subjects: 5988
Study 35926202 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical dilators inserted concurrently with misoprostol
Number of subjects: 347
Study 35926202 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone (control group)
Number of subjects: 347
Study 34913767 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi‐hepatic alternating radiotherapy (Group A)
Number of subjects: 68
Study 34913767 — intervention group
Group type: COMPARATOR
Intervention: Semi‐hepatic sequential radiotherapy (Group B)
Number of subjects: 68
Study 35278315 — intervention group
Group type: EXPERIMENTAL
Intervention: Headlamp
Number of subjects: 23
Study 35278315 — intervention group
Group type: COMPARATOR
Intervention: Night Vision Goggles (NVG)
Number of subjects: 23
Study 35278315 — intervention group
Group type: COMPARATOR
Intervention: Night Vision Goggles with Focusing Adaptors (NVG+A)
Number of subjects: 23
Study 35556932 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD during 0.05Hz maneuver
Number of subjects: 12
Study 35556932 — intervention group
Group type: COMPARATOR
Intervention: CON during 0.05Hz maneuver
Number of subjects: 12
Study 35556932 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD during 0.10Hz maneuver
Number of subjects: 12
Study 35556932 — intervention group
Group type: COMPARATOR
Intervention: CON during 0.10Hz maneuver
Number of subjects: 12
Study 33944876 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive therapeutic drug monitoring (TDM) with dose and interval adjustments based on scheduled monitoring of serum drug levels and antidrug antibodies (n=207)
Number of subjects: 411
Study 33944876 — intervention group
Group type: COMPARATOR
Intervention: Standard infliximab therapy without drug and antibody level monitoring (n=204)
Number of subjects: 411
Study 33944876 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive therapeutic drug monitoring (TDM)
Number of subjects: 411
Study 33944876 — intervention group
Group type: COMPARATOR
Intervention: Standard infliximab therapy
Number of subjects: 411
Study 36326260 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of sodium citrate and treprostinil in diluent with magnesium chloride (10 μL/h) with 15 unit-equivalent boluses (150 μL) at 3, 6, and 9 hours after initiation
Number of subjects: 40
Study 36326260 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm infusion site
Number of subjects: 40
Study 36326260 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh infusion site
Number of subjects: 40
Study 36326260 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdomen infusion site
Number of subjects: 40
Study 36326260 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannula depth (6 mm and 9 mm)
Number of subjects: 40
Study 35577477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg
Number of subjects: 3880
Study 35577477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg
Number of subjects: 3880
Study 35577477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3880
Study 35577477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 mg or 10 mg)
Number of subjects: 3880
Study 34930228 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR with CDSS
Number of subjects: 5901
Study 34930228 — intervention group
Group type: COMPARATOR
Intervention: EHR only
Number of subjects: 5901
Study 36048114 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-nicotine dose (3% JUUL)/nonpreferred flavor
Number of subjects: 15
Study 36048114 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose/preferred flavor
Number of subjects: 15
Study 36048114 — intervention group
Group type: EXPERIMENTAL
Intervention: High-nicotine dose (5% JUUL)/nonpreferred flavor
Number of subjects: 15
Study 36048114 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose/preferred flavor
Number of subjects: 15
Study 32290827 — intervention group
Group type: EXPERIMENTAL
Intervention: REACT (including Resource Directory)
Number of subjects: 800
Study 32290827 — intervention group
Group type: COMPARATOR
Intervention: Resource Directory only (RD only)
Number of subjects: 800
Study 36395550 — intervention group
Group type: EXPERIMENTAL
Intervention: beacon‐enhanced tones without alarms
Number of subjects: 44
Study 36395550 — intervention group
Group type: EXPERIMENTAL
Intervention: tremolo‐enhanced tones without alarms
Number of subjects: 44
Study 36395550 — intervention group
Group type: COMPARATOR
Intervention: standard pulse oximetry variable‐pitch tones plus alarms
Number of subjects: 44
Study 35897493 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature-based meditation
Number of subjects: 68
Study 35897493 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor meditation
Number of subjects: 68
Study 35897493 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 68
Study 34657218 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine gel
Number of subjects: 26
Study 32333538 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needling technique applied to Zusanli (ST36), Sanyinjiao (SP6), and Yinlingquan (SP9) for 30 min before HIPEC, along with intravenous injection of Ondansetron 30 min before HIPEC.
Number of subjects: 120
Study 32333538 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of Ondansetron 30 min before HIPEC (control group).
Number of subjects: 120
Study 36097264 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (MOD-EX, n=31)
Number of subjects: 145
Study 36097264 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity exercise (VIG-EX, n=31)
Number of subjects: 145
Study 36097264 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=35)
Number of subjects: 145
Study 33823782 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Diet
Number of subjects: 42
Study 33823782 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Aerobic Exercise Training (MIAET)
Number of subjects: 42
Study 33823782 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Fat Diet plus MIAET
Number of subjects: 42
Study 33823782 — intervention group
Group type: COMPARATOR
Intervention: All groups (including Low-Fat Diet, MIAET, and Low-Fat Diet plus MIAET)
Number of subjects: 42
Study 32207707 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroxide magnetophoresis using RPMF (20 mT, frequency 6.25 Hz, exposure time 20 min, No. 12)
Number of subjects: 65
Study 32207707 — intervention group
Group type: COMPARATOR
Intervention: Placebo-magnetotherapy of chondroxide
Number of subjects: 65
Study 32207707 — intervention group
Group type: COMPARATOR
Intervention: RPMF without local chondroprotective therapy
Number of subjects: 65
Study 32207707 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroxide magnetophoresis
Number of subjects: 65
Study 35853131 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviews (MI) - 4 sessions at weekly intervals
Number of subjects: 166
Study 35853131 — intervention group
Group type: COMPARATOR
Intervention: Control group - no intervention
Number of subjects: 166
Study 33844155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR)
Number of subjects: 120
Study 33844155 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (RTX)
Number of subjects: 120
Study 33844155 — intervention group
Group type: COMPARATOR
Intervention: Cladribine (CLA)
Number of subjects: 120
Study 33844155 — intervention group
Group type: COMPARATOR
Intervention: All groups (OCR, RTX, CLA)
Number of subjects: 120
Study 34851208 — intervention group
Group type: EXPERIMENTAL
Intervention: DesyncraTM
Number of subjects: 61
Study 34851208 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 61
Study 32719055 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed combination preventer and reliever therapy
Number of subjects: 288
Study 32719055 — intervention group
Group type: COMPARATOR
Intervention: Maintenance budesonide plus terbutaline reliever therapy
Number of subjects: 288
Study 36066248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with SMART goals set by children over six months.
Number of subjects: 0
Study 33779212 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPAS program
Number of subjects: 699
Study 33779212 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group (WLG)
Number of subjects: 699
Study 34994269 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple Pill (telmisartan 20 mg, amlodipine 2.5 mg, indapamide 1.25 mg)
Number of subjects: 1500
Study 34994269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 34994269 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple Pill
Number of subjects: 1500
Study 34088582 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 90
Study 36165681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional HBV vaccine
Number of subjects: 60
Study 36165681 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular HBV vaccine
Number of subjects: 60
Study 35265233 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous kyphoplasty (PKP) combined with calcitriol and calcium
Number of subjects: 36
Study 35265233 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous kyphoplasty (PKP)
Number of subjects: 36
Study 32123315 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine 30 mg orally twice daily
Number of subjects: 20
Study 32511226 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA (Ivermectin, Diethylcarbamazine, and Albendazole)
Number of subjects: 5761
Study 32511226 — intervention group
Group type: COMPARATOR
Intervention: DA (Diethylcarbamazine and Albendazole)
Number of subjects: 5761
Study 32511226 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA
Number of subjects: 5761
Study 32511226 — intervention group
Group type: COMPARATOR
Intervention: DA
Number of subjects: 5761
Study 34509996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive hydration
Number of subjects: 560
Study 34509996 — intervention group
Group type: COMPARATOR
Intervention: General hydration
Number of subjects: 560
Study 32816255 — intervention group
Group type: EXPERIMENTAL
Intervention: Care navigation strategies
Number of subjects: 21
Study 32816255 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual empowerment and knowledge of treatment benefits
Number of subjects: 21
Study 32816255 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal relationships
Number of subjects: 21
Study 32816255 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative problem solving
Number of subjects: 21
Study 32816255 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunities for care delivery improvement
Number of subjects: 21
Study 36138309 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter removal on postoperative day two after negative cystogram
Number of subjects: 24
Study 36138309 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital length of stay
Number of subjects: 24
Study 34140041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 0
Study 34140041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 34140041 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol
Number of subjects: 0
Study 34140041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37773124 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Brief Advice + Lung Age (VBA + LA)
Number of subjects: 1368
Study 37773124 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Brief Advice + Exhaled Carbon Monoxide (VBA + CO)
Number of subjects: 1368
Study 37773124 — intervention group
Group type: COMPARATOR
Intervention: Very Brief Advice (VBA)
Number of subjects: 1368
Study 33566122 — intervention group
Group type: COMPARATOR
Intervention: Omentectomy (group A, control arm)
Number of subjects: 251
Study 33566122 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentum preservation (group B, test arm)
Number of subjects: 251
Study 36193304 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroform
Number of subjects: 80
Study 36193304 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucalyptol
Number of subjects: 80
Study 36193304 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange Oil
Number of subjects: 80
Study 36193304 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylene
Number of subjects: 80
Study 34533783 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan
Number of subjects: 0
Study 34533783 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study 34533783 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan (early initiation)
Number of subjects: 0
Study 34390601 — intervention group
Group type: EXPERIMENTAL
Intervention: Angulated screw-retained crowns (AG)
Number of subjects: 56
Study 34390601 — intervention group
Group type: COMPARATOR
Intervention: Cemented crowns (CG)
Number of subjects: 56
Study 32277258 — intervention group
Group type: EXPERIMENTAL
Intervention: 85-dB music at 8 km/h
Number of subjects: 50
Study 32277258 — intervention group
Group type: EXPERIMENTAL
Intervention: 85-dB music at 10 km/h
Number of subjects: 50
Study 32277258 — intervention group
Group type: COMPARATOR
Intervention: 80-dB music at 8 km/h
Number of subjects: 50
Study 32277258 — intervention group
Group type: COMPARATOR
Intervention: 80-dB music at 10 km/h
Number of subjects: 50
Study 32277258 — intervention group
Group type: COMPARATOR
Intervention: 85-dB music at 12 km/h
Number of subjects: 50
Study 32277258 — intervention group
Group type: COMPARATOR
Intervention: No music at 8 km/h
Number of subjects: 50
Study 32277258 — intervention group
Group type: COMPARATOR
Intervention: No music at 10 km/h
Number of subjects: 50
Study 32277258 — intervention group
Group type: COMPARATOR
Intervention: No music at 12 km/h
Number of subjects: 50
Study 35910068 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 μg/kg of sufentanil
Number of subjects: 124
Study 35910068 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 μg/kg of sufentanil
Number of subjects: 124
Study 35910068 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 μg/kg of sufentanil
Number of subjects: 124
Study 35910068 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 124
Study 32891501 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery coaching intervention
Number of subjects: 98
Study 32891501 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 98
Study 36333766 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1 (n=400, 66.1% of the cohort)
Number of subjects: 605
Study 36333766 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 2 (n=102, 16.9% of the cohort)
Number of subjects: 605
Study 36333766 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 3 (n=103, 17% of the cohort)
Number of subjects: 605
Study 36333766 — intervention group
Group type: COMPARATOR
Intervention: High PEEP vs. low PEEP (ALVEOLI trial)
Number of subjects: 605
Study 36333766 — intervention group
Group type: COMPARATOR
Intervention: Conservative vs. liberal fluid management (FACTT trial)
Number of subjects: 605
Study 32201443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg intravenous over 10 min
Number of subjects: 54
Study 32201443 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.035 mg/kg intravenous over 1 min
Number of subjects: 54
Study 35582945 — intervention group
Group type: EXPERIMENTAL
Intervention: Client‐centred activities of daily living (CADL) intervention
Number of subjects: 145
Study 35582945 — intervention group
Group type: COMPARATOR
Intervention: Usual ADL (UADL) intervention
Number of subjects: 145
Study 35582945 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CADL and UADL interventions
Number of subjects: 145
Study 32986904 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy (AOT) - observation of uni/bimanual goal-directed actions followed by execution
Number of subjects: 8
Study 32986904 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - watched same-duration computer games and then performed the same actions in the same order as EG
Number of subjects: 8
Study 33306587 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic chain (KC) training
Number of subjects: 40
Study 33306587 — intervention group
Group type: COMPARATOR
Intervention: Conventional shoulder exercise training (CT)
Number of subjects: 40
Study 33545483 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of serum BPA (2.92 ng/mL)
Number of subjects: 1370
Study 33545483 — intervention group
Group type: COMPARATOR
Intervention: Low levels of serum BPA
Number of subjects: 1370
Study 33545483 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline eGFR levels
Number of subjects: 1370
Study 32497906 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial artery access (TRA)
Number of subjects: 673
Study 32497906 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral artery access (TFA)
Number of subjects: 673
Study 33909150 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathological characteristics (Tumor-infiltrating lymphocytes - TILs)
Number of subjects: 201
Study 33909150 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN-based TMB-H prediction model
Number of subjects: 201
Study 32561160 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0
Study 32561160 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (iGlar)
Number of subjects: 0
Study 36107563 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L polyethylene glycol/ascorbic acid (PEG/Asc)
Number of subjects: 172
Study 36107563 — intervention group
Group type: COMPARATOR
Intervention: Oral sodium sulfate (OSS)
Number of subjects: 172
Study 33341444 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX + cetuximab
Number of subjects: 5337
Study 32068423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive AS treatment
Number of subjects: 127
Study 32068423 — intervention group
Group type: COMPARATOR
Intervention: Repeated contact control
Number of subjects: 127
Study 36109825 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (6 mg once daily for 7 days)
Number of subjects: 252
Study 36109825 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 252
Study 33705748 — intervention group
Group type: EXPERIMENTAL
Intervention: EVO100
Number of subjects: 860
Study 33705748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 860
Study 36246990 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Dexmedetomidine
Number of subjects: 102
Study 36246990 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose Dexmedetomidine
Number of subjects: 102
Study 36246990 — intervention group
Group type: COMPARATOR
Intervention: Low-dose Dexmedetomidine
Number of subjects: 102
Study 34755269 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1.5 mg at baseline and 0.5 mg BID PO for 10 days)
Number of subjects: 116
Study 34755269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 34755269 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 116
Study 33261611 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically proxied milk consumption (using genetic variant rs4988235 or rs182549)
Number of subjects: 1000486
Study 33261611 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically proxied milk consumption
Number of subjects: 1000486
Study 36178956 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined short-axis out-of-plane and long-axis in-plane approach
Number of subjects: 110
Study 33372371 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 100
Study 33372371 — intervention group
Group type: COMPARATOR
Intervention: Intracervical normal saline infiltration
Number of subjects: 100
Study 32869246 — intervention group
Group type: EXPERIMENTAL
Intervention: Statement of truth before symptom validity tests (SIMS)
Number of subjects: 248
Study 32869246 — intervention group
Group type: COMPARATOR
Intervention: Statement of truth after symptom validity tests (SIMS)
Number of subjects: 248
Study 37355528 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative education
Number of subjects: 172
Study 37355528 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional module on realistic expectations
Number of subjects: 172
Study 33264819 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 207
Study 33264819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 34052927 — intervention group
Group type: EXPERIMENTAL
Intervention: Active photobiomodulation (PBM) treatment (pulsed near-infrared 808 nm Ga-Al-As laser, 250 mW, 8.8 J/cm2) for up to 12 weeks in addition to standard care
Number of subjects: 20
Study 34052927 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20
Study 33319355 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal and transperineal ultrasound before instrumental vaginal delivery
Number of subjects: 222
Study 33319355 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care (control) before instrumental vaginal delivery
Number of subjects: 222
Study 33526085 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 40
Study 33526085 — intervention group
Group type: COMPARATOR
Intervention: Active Control (AC)
Number of subjects: 40
Study 34865002 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 188
Study 34865002 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arms (not specified)
Number of subjects: 188
Study 34865002 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 188
Study 33223412 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 291
Study 33223412 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing TKA
Number of subjects: 291
Study 32819999 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive molecular testing plus routine microbiological testing
Number of subjects: 440